What the drug costs, who sets that number, and what changes on January 1st, 2027.
Read this first
This page is not built on clinical trial evidence. Cost, insurance coverage and legal status are commercial and policy facts, not scientific findings. They come from manufacturer announcements, regulator statements and payer policy, and they change on timescales of weeks.
Every figure here carries the date it was verified. Confirm against the source link before acting on a number.
How semaglutide pricing actually works
Why there is no single price
Four separate numbers get called "the price," and they rarely match.
| Number | What it is | Who it applies to |
|---|---|---|
| List price, or WAC | Wholesale acquisition cost, set by the manufacturer | Rarely paid directly. Matters most to people whose out-of-pocket cost is calculated from it |
| Self-pay or direct-to-patient | A manufacturer-set cash price outside insurance | People paying cash, usually through a manufacturer pharmacy channel |
| Insured copay or coinsurance | Set by the health plan, not the manufacturer | People with coverage for the specific indication |
| Net price | What the plan pays after rebates | Not visible to patients |
This structure explains the most common complaint on the subject, covered below.
Why did my out-of-pocket cost suddenly increase?
Because out-of-pocket cost is set by the plan, it can move without any change in the drug's price.
The usual causes are a new plan year resetting the deductible, a formulary change, the end of an introductory or savings offer period, a change in step therapy or prior authorisation status, or an employer removing weight-management coverage.
None of these are manufacturer price changes, which is why the drug's headline price can fall while an individual's bill rises.
The January 2027 list price change
What was announced
On 24 February 2026, Novo Nordisk announced that effective 1 January 2027 it will lower the list price, or wholesale acquisition cost, of Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5 mg, 1 mg and 2 mg, and Rybelsus tablets 7 mg or 14 mg, to $675 per month.1
The company described this as reductions of approximately 50 percent for Wegovy and 35 percent for Ozempic from the list price at the time of the announcement, applying to all doses of those presentations.1
Who this actually helps
Novo Nordisk stated the reduction is intended for patients whose out-of-pocket costs are linked to list price, naming individuals with high-deductible health plans or co-insurance benefit designs.1
The corollary follows from the pricing structure above. Someone with a flat copay generally sees no change from a list price move, because a copay is set by the plan.
What it does not change
The company stated explicitly that the list price change does not impact direct-to-patient, self-pay prices.1
Self-pay figures and introductory offers are therefore a separate track, set separately and revised on their own schedule. Self-pay figures and introductory offers change on their own schedule. Check the manufacturer's own pharmacy channel for the current number.
Insurance
Coverage depends on the indication, not the molecule
Semaglutide is approved under different brands for different purposes. Novo Nordisk lists the FDA-approved indications as obesity for Wegovy, type 2 diabetes for Ozempic, type 2 diabetes with chronic kidney disease for Ozempic injection, and comorbid cardiovascular disease for both Wegovy and Ozempic.1
Plans commonly cover the diabetes indication while excluding or restricting weight management. This is why two people can be prescribed the same molecule and face entirely different bills.
Prior authorisation and appeals
Prior authorisation is a plan process, not a regulatory one, so the criteria are set by the individual plan and published in its coverage policy. There is no national standard to cite.
What generalises: the decision is made against written criteria, those criteria are obtainable from the plan, and a denial is appealable through a process the plan is required to disclose. Requesting the specific coverage policy document before submitting is the step most often skipped.
A generic appeal template argues against the wrong standard, because criteria differ by plan.
How does step therapy work?
Step therapy is a plan rule requiring cheaper options to be tried and to fail before a more expensive one is covered. For GLP-1 medicines this commonly means documented attempts at diet and exercise, and sometimes a trial of an oral medication, before an injectable is approved.
The criteria are written into each plan's coverage policy, so the number of steps, what counts as a failed trial, and how long each must run all vary. The document that governs it is obtainable from the plan, and it is the thing to read before submitting rather than after a denial.
Does appealing a denial work?
Appeals are a defined right rather than a favour, and plans are required to disclose the process. Whether a given appeal succeeds depends on whether the denial reason can be answered with evidence.
The useful distinction is between a denial for missing documentation, which is often fixable, and a denial because the plan excludes the indication entirely, which usually is not. A plan that does not cover weight management will not be argued into covering it. Establishing which of the two you have received is the first step, and the denial letter states the reason.
Should I ask for a diabetes diagnosis so it gets covered?
No, and this deserves a direct answer because the question comes up often.
A prescriber can only record a diagnosis the person actually has. Recording one they do not have is misrepresentation to the insurer, and the consequences fall on both the prescriber, who risks their licence, and the patient, whose medical record then contains a condition they do not have. That record follows them into future insurance, future care and future prescribing decisions.
The legitimate versions of this conversation are different: asking whether an existing diagnosis such as prediabetes, established cardiovascular disease or chronic kidney disease changes which product and which indication apply. Semaglutide holds separate approvals across obesity, type 2 diabetes, cardiovascular risk and kidney disease.1 An accurate diagnosis someone already has may open a covered pathway. An invented one is a different act.
Do I qualify if I am just under the BMI threshold?
Coverage criteria are set by the plan and typically mirror the approved indications, which include a lower BMI threshold when a weight-related condition is present.1
Being under a threshold on one criterion does not automatically end the question, because a plan may allow a different route in through a comorbidity. What it does mean is that the decision rests on documented clinical facts rather than on how the request is worded. The plan's own policy document sets out which combinations qualify.
My plan covers the injection but not the tablet
Formularies treat different products separately even when the active ingredient is the same, because they are separate products with separate approvals and separate prices. Coverage of one implies nothing about the other.
If a specific formulation is needed for a clinical reason, that is the basis of a formulary exception request rather than a general appeal. If either formulation would do, the covered one is the shorter path.
Telehealth and subscription pricing
Does the price change as the dose increases?
It depends entirely on how the provider structures its pricing, and both models exist. Some price per dose or per strength, so cost rises with titration. Others charge a flat subscription across all strengths.
This is the single most useful question to ask before starting with any provider, because titration is expected rather than optional. A price quoted at 0.25 mg is not the price of the programme if the intended destination is 2.4 mg. Ask what the price is at every strength, not what the price is today.
Provider pricing changes frequently, and the pages currently ranking for those queries are largely written by the providers themselves.
What if a supply problem forces a change of provider or product mid-treatment?
Two things move. The price resets to whatever the new provider or product charges, and any introductory rate tied to the original arrangement is generally lost.
The clinical side is covered on the library page: no trial has studied switching mid-treatment, whether between providers or between molecules, so the effect on results is not established.
Are there providers that only accept certain patients?
Some services define their patient population narrowly, by sex, age, life stage or condition. That is a business decision rather than a clinical standard, and a narrower intake says nothing about quality in either direction.
The questions that matter are the same regardless: who prescribes, what monitoring is included, what happens at higher doses, and what the price is across the full range.
Can I use HSA or FSA funds for a cash-pay subscription?
Tax-advantaged health accounts cover qualified medical expenses, which generally requires a legitimate medical purpose and often documentation from a provider. A prescribed medicine for an approved indication normally fits that description more comfortably than a bundled subscription containing non-medical components.
Rules vary by plan and jurisdiction, and the account holder carries the consequences of a disallowed expense. This is a question for the plan administrator, and worth asking before rather than after.
Managing the cost
Can I stretch a supply by lowering the dose?
This is a dosing decision with a financial motive, and the two need separating.
The evidence position is on the library page: published protocols use fixed titration schedules, and no trial has tested extended intervals, split doses or staying below the maintenance dose to make a supply last. Real-world data show people commonly using doses well below those tested in trials, alongside weight loss lower than trial figures.3
There is also a practical risk specific to doing this for cost reasons. Dose manipulation of a pen or vial introduces measurement error, and the manufacturer's instructions assume the delivered dose.1 Anyone considering it should be doing so with the prescriber rather than instead of telling them.
Is it cheaper than what I was spending on food and alcohol?
Nobody has published a study on this, and the honest answer is that it is a personal calculation rather than a finding.
What the evidence does support is that the comparison should not be made against a single month. Benefit continues only while treatment continues, and roughly two-thirds of lost weight returned within a year of stopping in the withdrawal extension.4 A cost comparison that assumes a fixed course understates the commitment.
What if I have to stop because of the cost?
The evidence here is unusually clear and worth knowing before the decision rather than after.
Stopping led to the regain of roughly two-thirds of lost weight over the following year, with blood pressure, lipids, and glucose measures drifting back toward baseline.4 Continuing produced further loss over the same period, a difference of about 15 percentage points between the two paths.5
What has not been studied is anything in between. No trial has tested tapering, intermittent use, or a reduced maintenance dose as an alternative to stopping outright. Someone facing this decision has two studied options and no studied middle ground, which is worth saying to a prescriber directly.
Generics and patent timing
Where things stand
Generic availability differs by country, and this is the fastest-moving part of the cost picture. Patent expiry dates, national approvals and launch timing vary by jurisdiction.
Two things are worth stating plainly. Approval in one market is not evidence of approval in another. And a product marketed as a generic in a country where the patent has not expired is not a generic in the regulatory sense.
Verify against the national medicines regulator for the country in question rather than a general article, including this one.
Storage, travel and supply
Refrigeration
Injectable GLP-1 drugs require refrigeration as stated in their package inserts. The FDA recommends not using any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, because this can affect quality. The agency has received complaints of compounded GLP-1 drugs arriving warm or with inadequate ice packs.2
Permitted time out of refrigeration differs by product and presentation. That figure belongs to the package insert for the specific product, and should be read there rather than taken from a general guide.
Importing across borders
Import rules are national law, enforced at the border, and differ by country and by whether a valid prescription exists.
On the supply side, the FDA has established a green list import alert, 66-80, to stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the US supply chain. The alert does not apply to API from manufacturers found compliant on inspection, and the FDA states it does not create new limits on legal compounding.2
Personal importation should be checked against the customs and medicines authority of both origin and destination country before travelling.
The cheapest legitimate route
The honest answer is that it depends on which of the four pricing tracks applies to a given person, and that the ranking changes when offers change.
What does not change is the comparison set. The legitimate routes are insurance coverage, a manufacturer self-pay channel, and a state-licensed pharmacy filling a valid prescription. Products obtained outside those routes are covered on a separate page, along with what regulators have documented about them.
Novo Nordisk, in the same February 2026 announcement, stated that with supply of all doses fully available nationwide in the US there is no reason for patients to gamble with knock-off products produced by compounders.1 That is the manufacturer's position, and the manufacturer holds a commercial interest in it.
Sources
Novo Nordisk Inc. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access. 24 February 2026. prnewswire.com
US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug Alerts and Statements. Content current as of 15 June 2026. fda.gov
Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27(Suppl 2):66-88. Open access. pubmed.ncbi.nlm.nih.gov/40196933
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. Open access. pubmed.ncbi.nlm.nih.gov/35441470
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. Open access. pubmed.ncbi.nlm.nih.gov/33755728
Not medical or financial advice
Coverage decisions belong to your plan, and prescribing decisions belong to a qualified healthcare provider.
All figures verified 3 August 2026. Pricing, coverage and regulatory status change frequently. Re-verify against the linked sources before relying on any number here.